https://www.selleckchem.com/pr....oducts/puromycin-ami
The combination of improvements in the perinatal stabilisation period and early prediction of adverse outcomes may mitigate the need for specific postnatal management strategies. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.PURPOSE Existing cell-free DNA (cfDNA) methods lack the sensitivity needed for detecting minimal residual disease (MRD) following therapy. We developed a test for tracking hundreds of patient-specific mutations to detect MRD with a 1000-fold lower error rat
Like
Comment
Share
